Gilead Sciences Inc. Blog | Talkmarkets | Page 1
No data available
No data available
Latest Posts
1 to 16 of 554 Posts
1 2 3 ... 35
Gilead Analyst: Coronavirus Drug, Arcus Collaboration Make Biopharma A Buy
Article By: Benzinga Wednesday, June 3, 2020 11:50 AM EDT
Geoffrey Porges upgraded Gilead Sciences from Market Perform to Outperform and raised the price target from $85 to $94.
In this article: GILD Also: RCUS
Read
Gilead Falls After Phase 3 Remdesivir 10-Day Trial Failed To Reach Significance
Article By: Tyler Durden Monday, June 1, 2020 9:50 AM EDT
The news sent ES futures lower, with the Emini down 8 points and Dow futures sliding back in the red.
In this article: GILD, DJI, SPX
Read
E Market Briefing For Monday, May 25
Article By: Gene Inger Monday, May 25, 2020 12:11 AM EDT
Amidst the obvious backdrop the market forges ahead, with a 'Fed Put' as the driving force; and with what I call a handful of 'super-caps' at the helm; and a little better performance in so-called value sectors.
In this article: HTZ, GILD Also: DRI, NYA
Read
8 Monster Stocks To Watch For The Week Of May 25
Article By: Michael J. Kramer Sunday, May 24, 2020 1:42 PM EDT
The market left itself in a vulnerable spot to start the final week of May. Trends overall are not all that bullish as the index continues to post signs of fading momentum.
In this article: AMD, QQQ, GILD, MSFT, NFLX, SPY, BABA, ROKU
Read
Are Biotech ETFs In Trouble As Coronavirus Dims Guidance?
Article By: Zacks Investment Research Saturday, May 9, 2020 7:49 PM EDT
Although the coronavirus seems to be opening up opportunities for biotech companies, it is dampening their guidance as well. Despite impressive results, most of these biotechs have been seeing declining share prices since the earnings releases.
In this article: ALXN, IBB, AMGN, BIIB, GILD, BBH, XBI
Read
Gilead CEO Says Remdesivir Will Get To Patients Early This Week
Article By: The Fly Sunday, May 3, 2020 1:15 PM EDT
Gilead Sciences CEO Daniel O'Day said the company plans to get remdesivir to patients in the early part of this next week.
In this article: GILD
Read
"Remdesivir Is Probably Worthless" - A Trauma Surgeon Exposes "Drug Company's Shenanigans"
Article By: Tyler Durden Sunday, May 3, 2020 5:51 AM EDT
Markets got excited (briefly) this week about a study finding a Gilead Sciences drug helped coronavirus patients heal a little more quickly. But that was all the trial found: Remdesivir isn’t the miracle cure that will get us all out of lockdowns.
In this article: GILD
Read
E Market Briefing For Monday, May 4
Article By: Gene Inger Saturday, May 2, 2020 11:20 PM EDT
Financial problems need a medical solution; if that takes too long, it will enhance downside volatility.
In this article: AZN, PFE, GILD, TSLA, SPY Also: F
Read
Week In Review: How Trump's Policies Moved Stocks - Saturday, May 2
Article By: The Fly Saturday, May 2, 2020 4:10 PM EDT
We highlight the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Donald Trump and his administration with this weekly recap.
In this article: ACM, CAG, CAT, CBI, EXP, FLR, GVA, HRL, MLM, PPC, PWR, TSN, VMC, USCR, CMCSA, CMCSK, GILD, SAFM, J
Read
Week In Review: Sellers Show Up After Long Hiatus
Article By: Adam Sarhan Friday, May 1, 2020 4:56 PM EDT
It was an ugly week on Wall Street. The market broke out of its latest trading range and rallied sharply in the first half of the week but sellers showed up in the second half, erased those gains, and negated the breakout.
In this article: AAPL, AMZN, SPX, GOOGL, PFE, GILD
Read
Gilead Reports Q1 Adjusted EPS $1.68, Consensus $1.57
Article By: The Fly Thursday, April 30, 2020 4:10 PM EDT
Total product sales for the first quarter of 2020 were $5.5 billion compared to $5.2 billion for the same period in 2019.
In this article: GILD
Read
Approval Of Gilead's Remdesivir 'All But Final,' Says Piper Sandler
Article By: The Fly Thursday, April 30, 2020 5:39 AM EDT
Piper Sandler analyst Tyler Van Buren, following yesterday's developments, believes FDA approval of Gilead's remdesivir as a treatment for COVID-19 is "all but final".
In this article: GILD
Read
Gilead Rises, Boosts Market As Remdesivir COVID-19 Trial Meets Primary Target
Article By: The Fly Wednesday, April 29, 2020 12:12 PM EDT
Wells Fargo does not see a significant commercial opportunity for remdivisir given likely free drug supply.
In this article: GILD
Read
Stocks Tumble, Gilead Crashes After FT Reports Gilead's Remdesivir "Flops" In First Clinical Trial
Article By: Tyler Durden Thursday, April 23, 2020 1:00 PM EDT
The FT just reported that Gilead's "miracle drug" remdesivir has flopped in during its first clinical trial.
In this article: GILD, SPX
Read
Gilead Stock Crashed Despite Potential Cure For COVID-19! Buy Or Sell?
Video By: Kiana Danial Tuesday, April 21, 2020 8:00 PM EDT
Gilead's stock crashed despite the breaking positive news on April 20th which suggested they may have a potential cure for the COVID-19 which is caused by the new coronavirus.
In this video: GILD
Watch
Banking & Finance Expected To Get Crushed
Article By: Chris Vermeulen Sunday, April 19, 2020 10:00 PM EDT
After news of Gildead's success curing all 125 COVID-19 patients that were tested with its drug, stocks are popping 2-5% but the damage to the financial markets has already been done.
In this article: SPY, GILD, XLF, UCC
Read
1 to 16 of 554 Posts
1 2 3 ... 35